Suchergebnisse - "Richter, Joshua"

PubPharm (134)

1

Pityriasis lichenoides et varioliformis acuta in a patient treated with cevostamab

enthalten in: JAAD case reports | 2024

von Orloff, J. | Patel, D. | Powers, C. | +4

2

Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma : A systematic review and meta-analysis

enthalten in: American journal of hematology | 2024

von Costa, B. | Costa, T. | Pak, K. | +4

3

Like a bridge over troubled water : keeping the myeloma down en route to CAR-T

enthalten in: Blood cancer journal | 2024

von Richter, J.

4

Soluble B-cell maturation antigen in multiple myeloma

enthalten in: American journal of hematology | 2024

von Costa, B. | Ortiz, R. | Lesokhin, A. | +1

5

Practical Aspects of Immunotherapy : A Report from the 20th International Myeloma Society (IMS) Annual Meeting

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Raje, N. | Cohen, A. | Patel, K. | +3

6

Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma : A comparative systematic review and meta-analysis

enthalten in: American journal of hematology | 2024

von Costa, B. | Costa, T. | Saravia, S. | +4

7

T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma : When the cure fails!

enthalten in: British journal of haematology | 2024

von Richter, J.

8

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma : an indirect treatment comparison

enthalten in: Leukemia & lymphoma | 2024

von Weisel, K. | Dimopoulos, M. | Beksac, M. | +7

9

Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

enthalten in: Blood advances | 2024

von Shah, U. | Moshier, E. | Derkach, A. | +20

CommentIn: Blood Adv. 2024 Jan 9;8(1):234-235. - PMID 38194241

10

In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

enthalten in: Future oncology (London, England) | 2024

von Rifkin, R. | Costello, C. | Birhiray, R. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]